Clinical Trial Update: Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial update examining progressively decreasing titration schedules of bifeprunox in individuals with schizophrenia or bipolar disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Bifeprunox (bifeprunox)

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: COMPLETED